Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
Apply
IO102-IO103 & Pembrolizumab
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step